Chalcogen Bonded Directly To Ring Carbon Of The Hetero Ring Patents (Class 514/460)
-
Publication number: 20100216874Abstract: The invention provides olive-derived hydroxytyrosol. According to one aspect of the invention, vegetation water is collected from olives. Acid is added to stabilize the vegetation water and prevent fermentation. The mixture is incubated to allow oleuropein to convert to hydroxytyrosol, and then fractionated to separate hydroxytyrosol from other components. The hydroxytyrosol is useful as a therapeutic and anti-oxidant for a variety of health purposes, including for the treatment of skin damage. In addition, the hydroxytyrosol is useful as a natural anti-bacterial, anti-viral and fungicidal product for agricultural and pest control applications.Type: ApplicationFiled: May 10, 2010Publication date: August 26, 2010Inventor: Roberto Crea
-
Publication number: 20100212036Abstract: The present invention provides for methods of treating and preventing cardiac hypertrophy. Class I HDACs, which are known to participate in regulation of chromatin structure and gene expression, have generally been considered as pro-hypertrophic in their action. However, the present invention demonstrates that inhibition of certain Class I HDACs should be avoided in the treatment of cardiac hypertrophy, thereby pointing toward selective, and not global, inhibition of Class I HDACs. In particular, the present invention provides for selective inhibition of HDACs 1 and/or 2, and the avoidance of inhibition of HDAC3.Type: ApplicationFiled: September 29, 2009Publication date: August 19, 2010Inventors: Eric N. Olson, Lawrence Melvin, Rusty L. Montgomery
-
Publication number: 20100204195Abstract: Amorphous HMG CoA reductase inhibitors, especially amorphous atorvastatin, are described. Also described are pharmaceutical combinations comprising amorphous HMG CoA reductase inhibitors in combination with cholesterol absorption inhibitors or fibrates. A method of manufacturing the compositions using a hot melt extrusion process are also described.Type: ApplicationFiled: July 28, 2008Publication date: August 12, 2010Applicant: CIPLA LIMITEDInventors: Amar Lulla, Geena Malhotra
-
Publication number: 20100204254Abstract: The present invention discloses statins (3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors) consistently and significantly increased endothelial cell thrombomodulin protein and functional activity. Statins also abrogated the downregulation of thrombomodulin that occurs in response to radiation injury. These results indicate that preserving or restoring endothelial thrombomodulin expression and function by statins may be useful in a variety of disorders associated with widespread endothelial dysfunction such as sepsis, adult respiratory distress syndrome, and normal tissue radiation injury.Type: ApplicationFiled: January 29, 2010Publication date: August 12, 2010Applicant: The University of Arkansas for Medical SciencesInventors: Martin K. Hauer-Jensen, Louis M. Fink, Jawahar Lal Mehta, Junru Wang, Jacob Joseph
-
Publication number: 20100203175Abstract: The invention relates to the use, as an active ingredient, of at least one substance that promotes the deglycation of AGEs for preparing a composition, especially for limiting the presence of AGEs in a tissue. The invention particularly relates to the use of such a substance for preparing a composition intended to prevent and/or combat a reduction in flexibility and/or plasticity and/or elasticity and/or functionality of a tissue, and/or to prevent and/or combat the ageing of a tissue, by promoting the deglycation of AGEs in the tissue, said tissue preferably being the skin, or the tissue wall of a blood vessel or of an organ.Type: ApplicationFiled: July 9, 2008Publication date: August 12, 2010Applicant: BASF BEAUTY CARE SOLUTIONS FRANCE S.A.S.Inventors: Nabil ABDUL-MALAK, Cecile ALTOBELLI, Eric PERRIER
-
Patent number: 7772378Abstract: Glucopyranosyl-substituted (hetero)arylethynyl-benzene derivatives of the general formula I where the groups R1 to R6 as well as R7a, R7b, R7c are defined according to claim 1, including the tautomers, the stereoisomers thereof, the mixtures thereof and the salts thereof. The compounds according to the invention are suitable for the treatment of metabolic disorders.Type: GrantFiled: February 22, 2006Date of Patent: August 10, 2010Assignee: Boehringer Ingelheim International GmbHInventors: Frank Himmelsbach, Matthias Eckhardt, Peter Eickelmann, Leo Thomas, Edward Leon Barsoumian
-
Patent number: 7767708Abstract: An improved weight and growth stimulant for domesticated animals such as cattle, pigs and sheep is comprised of an anabolic agent that is subcutaneously administered in the form of a dual release implant formulation. Increased gains are particularly improved when zeranol is administered in an immediate-release and controlled-release formulation which allows for a one-time dosage injection.Type: GrantFiled: November 1, 1999Date of Patent: August 3, 2010Assignee: Schering-Plough Animal Health Corp.Inventors: Shih Chung, Thomas J. Kennedy, Peter James Knight, Daniel S. Robins, Zezhi Jesse Shao
-
Publication number: 20100190732Abstract: This invention relates to the use of pterosin compounds of formula I for treating diabetes including type I and type II. Also disclosed is the use of the pterosin compounds for treating obesity.Type: ApplicationFiled: January 26, 2010Publication date: July 29, 2010Applicants: Taipei Medical University, National Taiwan University, National Tsing Hua University, DCB-USA, LLCInventors: Feng-Lin Hsu, Shing-Hwa Liu, Biing-Jiun Uang
-
Publication number: 20100190845Abstract: The present invention is directed to a method of treating cancer in a subject in need of such a treatment by administering an inhibitor of ATP synthase in a pharmaceutically effective amount, preferably, the inhibitor contains one pyrone ring. The present invention also provides for a pharmaceutical composition comprising an inhibitor of ATP synthase, preferably, the inhibitor is aurovertin B.Type: ApplicationFiled: January 26, 2009Publication date: July 29, 2010Applicant: NATIONAL TAIWAN UNIVERSITYInventors: Hsueh-Fen Juan, Hsin-Yi Chang, Tsui-Chin Huang, Chun-Hua Hsu, Wen-Hung Kuo, King-Jen Chang
-
Patent number: 7763649Abstract: A method of controlling (e.g., influencing or affecting) connexin 43 expression in a subject may include administering to the subject an effective amount of a pharmaceutically acceptable formulation. In some embodiments, controlling connexin 43 expression in a subject may effectively treat cardiac arrhythmia and/or cancerous and pre-cancerous cells in a subject. The pharmaceutically acceptable formulation may include a synthetic analog or derivative of a carotenoid. The subject may be administered a carotenoid analog or derivative, either alone or in combination with another carotenoid analog or derivative, or co-antioxidant formulation. The carotenoid analog may include a conjugated polyene with between 7 to 14 double bonds. The conjugated polyene may include an acyclic alkene including at least one substituent and/or a cyclic ring including at least one substituent. In some embodiments, a carotenoid analog or derivative may include at least one substituent.Type: GrantFiled: March 4, 2004Date of Patent: July 27, 2010Assignee: Cardax Pharmaceuticals, Inc.Inventors: Samuel Fournier Lockwood, Sean O'Malley, David G. Watumull, Laura M. Hix, Henry Jackson, Geoff Nadolski
-
Patent number: 7763657Abstract: This present invention relates to novel compounds, isomer thereof or pharmaceutically acceptable salt thereof as vanilloid receptor (Vanilloid Receptor 1; VR1; TRRPV1) antagonist; and a pharmaceutical composition containing the same. The present invention provides a pharmaceutical composition for preventing or treating a disease such as pain, migraine, arthralgia, neuralgia, neuropathies, nerve injury, skin disorder, urinary bladder hypersensitiveness, irritable bowel syndrome, fecal urgency, a respiratory disorder, irritation of skin, eye or mucous membrane, stomach-duodenal ulcer, inflammatory diseases, ear disease, and heart disease.Type: GrantFiled: March 15, 2006Date of Patent: July 27, 2010Assignee: Amorepacific CorporationInventors: Hee-Doo Kim, Young-Ger Suh, Hyeung-Geun Park, Uh Taek Oh, Seol Rin Park, Joo Hyun Kim, Mi Jung Jang, Young-Ho Park, Song Seok Shin, Sun-Young Kim, Jin Kwan Kim, Yeon Su Jeong, Ki-Wha Lee, Jin Kyu Choi, Kyung Min Lim, Hyun Ju Koh, Joo Hyun Moh, Sung-Il Kim, Byoung Young Woo
-
Publication number: 20100183598Abstract: Disclosed herein, in certain embodiments, is a method for treating a cardiovascular disorder. In some embodiments, the method comprises co-administering an inhibitor of inflammation and an agent used to treat a cardiovascular disorder.Type: ApplicationFiled: November 12, 2009Publication date: July 22, 2010Applicant: CAROLUS THERAPEUTICS, INC.Inventors: Joshua Robert Schultz, Benedikt Vollrath, Court Turner
-
Publication number: 20100178337Abstract: The present invention relates to a composition comprising at least one active ingredient with low aqueous solubility, said active ingredient being present therein in a form noncovalently associated with nanoparticles formed by at least one POM polymer of formula (I), and in which said active ingredient is present in a proportion of at least 5 ?mol/g of POM. It is also directed towards the use of such nanoparticles, noncovalently associated with an active ingredient, with a view to increasing the aqueous solubilization of said active ingredient.Type: ApplicationFiled: December 18, 2009Publication date: July 15, 2010Applicant: Flamel TechnologiesInventors: Rémi MEYRUEIX, Rafael Jorda, Gauthier Pouliquen, You-Ping Chan, Olivier Breyne
-
Publication number: 20100179191Abstract: Glucopyranosyl-substituted cyclopropyl-benzene derivatives defined according to claim 1, including the tautomers, the stereoisomers thereof, the mixtures thereof and the salts thereof. The compounds according to the invention are suitable for the treatment of metabolic disorders.Type: ApplicationFiled: August 14, 2007Publication date: July 15, 2010Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventors: Frank Himmelsbach, Matthias Eckhardt, Peter Eickelmann
-
Publication number: 20100173856Abstract: Methods for producing a composition that includes an active agent, nutraceutical and pharmaceuticals compositions, and methods for ameliorating and/or treating a disease using the composition that includes an active substance are described herein. More particularly, methods for producing a composition that contains one or more active substances such as oleocanthal, pharmaceutical compositions that include one or more active substances such as oleocanthal, and methods of ameliorating and/or treating inflammation using compositions that contains one or more active substances such as oleocanthal are described.Type: ApplicationFiled: March 22, 2010Publication date: July 8, 2010Applicant: Olive Denk, Inc.Inventor: Erwin Denk
-
Publication number: 20100160298Abstract: The topical use of 5,6,7-trihydroxyheptanoic acid and analogs alone or in combination with histamine antagonists and/or mast cell stabilizers is disclosed for the treatment of ocular allergy.Type: ApplicationFiled: February 8, 2010Publication date: June 24, 2010Applicant: Alcon Research, Ltd.Inventors: Peter G. Klimko, Clay Beauregard
-
Publication number: 20100158996Abstract: A novel therapeutic agent for hyperlipidemia, which is an ester compound represented by the formula (1?) (wherein R1 and R2 are each hydrogen atom or optionally substituted aryl, etc.; X is —COO— or —CON(R10)—; R3 and R4 are each hydrogen atom, C1-C6 alkyl or C1-C6 alkoxy, etc.; R5, R6 and R7 are each hydrogen atom, C1-C6 alkyl or C1-C6 alkoxy, etc.; R9 and R9 are each independently hydrogen atom, C1-C6 alkyl, —CON(R18) (R19) or —COO(R20), etc.; ring A, ring B and ring C are each independently aryl or heterocycle residue, etc.; Alk1 and Alk2 are each independently alkanediyl, etc.; l and m are each an integer of 0 or 1 to 3) or a prodrug thereof, or a pharmaceutically acceptable salt of either. The therapeutic agent selectively inhibits MTP in the small intestine, thus causes no such side effect as a fatty liver.Type: ApplicationFiled: February 12, 2010Publication date: June 24, 2010Inventors: Atsushi Hagiwara, Yasuhiro Ohe, Naoya Odani, Shizue Watanabe, Taku Ikenogami, Takashi Kawai, Kenya Madono, Toshio Taniguchi
-
Patent number: 7741344Abstract: A process for resolution of racemic BEL into its individual enantiomeric constituents by chiral HPLC. A method for determining the role of specific isoforms of iPLA2 in biologic processes.Type: GrantFiled: March 19, 2003Date of Patent: June 22, 2010Assignee: Washington University in St. LouisInventor: Richard W. Gross
-
Publication number: 20100150890Abstract: It is intended to provide a safe composition for preventing or treating obesity or related complications which has an autonomic nervous control effect, in particular, an effect of enhancing sympathetic nervous activity and an effect of promoting energy metabolism. Thus, a medicinal composition, a food or a drink containing 2,3-dihydro-3,5-dihydroxy-6-methyl-4H-pyran-4-one and having an autonomic nervous control effect and an effect of promoting energy metabolism is provided.Type: ApplicationFiled: March 28, 2008Publication date: June 17, 2010Applicant: SUNTORY HOLDINGS LIMITEDInventors: Yoshinori Beppu, Nobuo Tsuruoka, Tomohiro Rogi, Hajime Komura, Katsuya Nagai
-
Publication number: 20100144685Abstract: This document involves methods and materials related to inhibiting cyclin D polypeptide activity. For example, this document provides methods and materials that can be used to (1) identify mammals or cells in need of cyclin D polypeptide inhibition and (2) administer an agent capable of inhibiting cyclin D polypeptide activity.Type: ApplicationFiled: October 10, 2007Publication date: June 10, 2010Inventors: Rodger E. Tiedemann, Alexander Keith Stewart, Aaron David Schimmer, Xinliang Mao
-
Publication number: 20100144862Abstract: The invention relates to the use of substituted pyranone acid derivatives and of their physiologically acceptable salts for producing medicaments for treating the metabolic syndrome.Type: ApplicationFiled: July 16, 2009Publication date: June 10, 2010Applicant: SANOFI-AVENTISInventors: Harm BRUMMERHOP, Siegfried STENGELIN, Hubert HEUER, Susanne KILP, Andreas HERLING, Thomas KLABUNDE, Dieter KADEREIT, Matthias URMANN
-
Publication number: 20100137284Abstract: The combination of nitric oxide generating compounds which are not dependent upon aldehyde dehydrogenase for bioactivation, or are specifically targeted to nNOS or the sarcoplasmic reticulum of cardiac muscle cells, and xanthine oxidase inhibitors are effective in the treatment of heart disease, specifically congestive heart failure and ischemic coronary disease. This treatment is particularly effective in patients who have particularly heavy oxidative burdens, e.g. diabetics, patients with lung disorders, patients with sickle cell anemia and patients of Asian descent.Type: ApplicationFiled: June 25, 2009Publication date: June 3, 2010Inventors: Jonathan S. Stamler, Gregory T. Went
-
Plasminogen Activator Inhibitor-1 Inhibitors and Methods of Use Thereof to Modulate Lipid Metabolism
Publication number: 20100137194Abstract: The invention relates to plasminogen activator-1 (PAI-1) inhibitor compounds and uses thereof in the treatment of any disease or condition associated with elevated PAI-1. The invention includes, but is not limited to, the use of such compounds to modulate lipid metabolism and treat conditions associated with elevated PAI-1, cholesterol, or lipid levels.Type: ApplicationFiled: November 23, 2009Publication date: June 3, 2010Applicants: EASTERN MICHIGAN UNIVERSITYInventors: Daniel A. Lawrence, Cory Emal, Jacqueline Cale, Enming J. Su, Mark Warnock, Shih-Hon Li, Jeanne A. Cupp -
Publication number: 20100129311Abstract: The present invention relates to new phenylalanine amide inhibitors of ATP-sensitive potassium channels, pharmaceutical compositions thereof, and methods of use thereof.Type: ApplicationFiled: November 23, 2009Publication date: May 27, 2010Applicant: AUSPEX PHARMACEUTICALS, INC.Inventor: Thomas G. Gant
-
Publication number: 20100130495Abstract: The present invention relates to novel compounds of formula I and therapeutically acceptable salts thereof, their pharmaceutical compositions, processes for making them and their use as therapeutic methods for treatment and/or prevention of various diseases.Type: ApplicationFiled: November 6, 2009Publication date: May 27, 2010Applicant: ASTRAZENECA ABInventors: Rickard FORSBLOM, Kim PAULSEN, Didier ROTTICCI, Ellen SANTANGELO, Magnus WALDMAN
-
Publication number: 20100130600Abstract: The invention provides methods of treating and prognosing atherosclerosis and lipid response to statin treatment by determining the presence or absence of haplotypes at the lipoprotein lipase locus. In one embodiment, the invention is practiced by evaluating the prognosis of vascular grafts in an individual undergoing statin treatment by determining the presence or absence of haplotypes at the lipoprotein locus.Type: ApplicationFiled: March 28, 2008Publication date: May 27, 2010Applicant: CEDARS-SINAI MEDICAL CENTERInventors: Mark O. Goodarzi, Kent D. Taylor, Maren T. Scheuner, Xiuqing Guo, Prediman K. Shah, Jerome I. Rotter
-
Publication number: 20100125102Abstract: The present invention relates to compounds having estrogenic activity selected from the group consisting of Loliolide, (4S,6S)-4-Hydroxy-6-nonadecyl-tetrahydro-pyran-2-one, (4R,6S)-4-Hydroxy-6-nonadecyl-tetrahydro-pyran-2-one and analogues thereof. The compounds of the present invention are selective estrogen receptor modulator, which can selectively activate ER? and simultaneously express high estrogenic activity, and also can be applied as medical or food compositions to improve estrogen deficiency-related symptoms.Type: ApplicationFiled: April 3, 2009Publication date: May 20, 2010Applicant: NATIONAL TAIWAN UNIVERSITYInventors: Ching-Jang Huang, Ssu-Ching Wang, Yueh-Hsiung Kuo, Yong-Han Hong, Bi-Fong Lin, Chin Hsu
-
Patent number: 7718643Abstract: The instant invention provides a pharmaceutical composition comprised of a cholesterol absorption inhibitor and an HMG-CoA reductase inhibitor, one or more anti-oxidants, microcrystalline cellulose, hydroxypropyl methylcellulose, magnesium stearate and lactose. The composition need not contain ascorbic acid in order to obtain desirable stability.Type: GrantFiled: May 26, 2009Date of Patent: May 18, 2010Assignee: Schering CorporationInventor: Wing-Kee Philip Cho
-
Publication number: 20100119482Abstract: Methods are provided for treating a subject for a condition. In accordance with the subject methods, at least a portion of a subject's autonomic nervous system is modulated during at least one predetermined phase of the subject's menstrual cycle to alter the parasympathetic activity/sympathetic activity ratio in a manner that is effective to treat the subject for the condition. The subject methods find use in the treatment of a variety of different conditions, including various disease conditions, that increase in severity and/or occurrence during one or more phases of the menstrual cycle. Also provided are systems and kits for use in practicing the subject methods.Type: ApplicationFiled: December 24, 2009Publication date: May 13, 2010Inventors: Anthony Joonkyoo Yun, Partic Yuarn-Bor Lee
-
Publication number: 20100119600Abstract: Medicaments and therapeutic compositions comprise Red Yeast Rice extract and omega-3 polyunsaturated fatty acids and/or derivatives thereof, e.g., DHA, derivatives of DHA, EPA, derivatives of EPA or mixtures thereof. One source of the fatty acids or derivatives thereof is fish oil. The compositions are useful for lowering cholesterol and/or triglyceride levels in a subject.Type: ApplicationFiled: December 3, 2009Publication date: May 13, 2010Inventor: Joar Opheim
-
Publication number: 20100113460Abstract: Disclosed are compounds having the ability to inhibit cytochrome P450 2A6, 2A13, and/or 2B6 and tobacco products comprising them. Also disclosed are pharmaceutical compositions comprising them.Type: ApplicationFiled: March 20, 2008Publication date: May 6, 2010Applicant: Givaudan SAInventors: Boris Schilling, Wolf D. Woggon, Antoinette Chougnet, Thierry Granier, Georg Frater, Andreas Hanhart
-
Patent number: 7709515Abstract: The present invention relates to novel ether compounds, compositions comprising ether compounds, and methods useful for treating and preventing cardiovascular diseases, dyslipidemias, dysproteinemias, and glucose metabolism disorders comprising administering a composition comprising an ether compound. The compounds, compositions, and methods of the invention are also useful for treating and preventing Alzheimer's Disease, Syndrome X, peroxisome proliferator activated receptor-related disorders, septicemia, thrombotic disorders, obesity, pancreatitis, hypertension, renal disease, cancer, inflammation, and impotence. In certain embodiments, the compounds, compositions, and methods of the invention are useful in combination therapy with other therapeutics, such as hypocholesterolemic and hypoglycemic agents.Type: GrantFiled: November 16, 2004Date of Patent: May 4, 2010Assignee: Esperion Therapeutics, Inc.Inventor: Jean-Louis Henri Dasseux
-
Publication number: 20100105768Abstract: Disclosed is a method for inhibiting the growth of mold on building materials by application onto and/or incorporation into the building material of a mold-inhibiting composition comprising dehydroacetic acid or a salt thereof and, optionally, an additional fungicidal agent such as a quaternary ammonium compound. A preferred application of the method is the inhibition of mold growth on plasterboard (drywall).Type: ApplicationFiled: October 7, 2009Publication date: April 29, 2010Inventors: Xiao Jiang, Leigh Walker
-
Patent number: 7704526Abstract: A sustained-release composition for oral administration of a drug, comprising the drug, a mixture of sodium alginate and xanthan gum as a carrier for sustained release and a mixture of hydroxypropyl methylcellulose and propylene glycol alginate as a gel hydration accelerator, which is capable of maintaining a constant drug level in blood for 24 hours or more. Due to rapid gel hydration without forming a non-gelated core, the drug release rate follows zero order kinetics and does not significantly vary with the degree of gastrointestinal motility.Type: GrantFiled: August 27, 2003Date of Patent: April 27, 2010Assignee: Hanmi Pharm. Co., LtdInventors: Jong-Soo Woo, Moon-Hyuk Chi
-
Publication number: 20100098640Abstract: Provided herein are chelating agents and metal chelates that are useful in diagnostic and therapeutic applications. The uses of metal chelates provided herein include their use as contrast agents in medical imaging modalities, such as magnetic resonance imaging (MRI).Type: ApplicationFiled: June 20, 2006Publication date: April 22, 2010Inventors: Seth M. Cohen, David T. Puerta
-
Publication number: 20100099661Abstract: Compounds having antibacterial activity are disclosed. The compounds have the following structure (I): including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein Q1, Q2, Q3, R8 and R9 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.Type: ApplicationFiled: June 18, 2009Publication date: April 22, 2010Applicant: Achaogen, Inc.Inventors: James Bradley Aggen, Adam Aaron Goldblum, Martin Sheringham Linsell, Paola Dozzo, Heinz Ernst Moser, Darin James Hildebrandt, Micah James Gliedt
-
Publication number: 20100092479Abstract: The present invention features compositions, methods, and kits useful in the treatment of viral diseases. In certain embodiments, the viral disease is caused by a single stranded RNA virus, a flaviviridae virus, or a hepatic virus. In particular embodiments, the viral disease is viral hepatitis (e.g., hepatitis A, hepatitis B, hepatitis C, hepatitis D, hepatitis E).Type: ApplicationFiled: August 17, 2009Publication date: April 15, 2010Applicant: CombinatoRx (Singapore) Pte. Ltd.Inventors: Lisa M. Johansen, Christopher M. Owens
-
Publication number: 20100086602Abstract: The present invention provides a novel nanotechnology-based strategy for therapeutic neovascularization. Said statin-loaded nanoparticle allows local delivery of statin and thus improves therapeutic efficacy of several kind of diseases which may treated by statin such as ischemic neovascularization.Type: ApplicationFiled: August 30, 2007Publication date: April 8, 2010Inventor: Kensuke Egashira
-
Patent number: 7691901Abstract: A method for inhibiting and/or ameliorating the occurrence of diseases in a human subject whereby a subject is administered a carotenoid analog or derivative, either alone or in combination with another carotenoid analog or derivative. In some embodiments, the administration of analogs or derivatives of carotenoids may inhibit and/or ameliorate the occurrence of diseases in subjects. In some embodiments, analogs or derivatives of carotenoids may be water-soluble and/or water dispersible. Maladies that may be treated with analogs or derivatives of carotenoids embodied herein may include diseases that provoke or trigger an inflammatory response. In an embodiment, asthma may be treated with analogs or derivatives of carotenoids embodied herein. In an embodiment, administering analogs or derivatives of carotenoids embodied herein to a subject may control or affect the bioavailability of eicosanoids. In an embodiment, atherosclerosis may be treated with analogs or derivatives of carotenoids embodied herein.Type: GrantFiled: April 14, 2005Date of Patent: April 6, 2010Assignee: Cardax Pharmaceuticals Inc.Inventors: Samuel Fournier Lockwood, Sean O'Malley, Henry Jackson, Geoff Nadolski
-
Publication number: 20100081632Abstract: A method of assaying protein-protein interactions associated with proteins involved in lipid pathways using a protein fragment complementation assays, said method comprising the steps of: (a) identifying protein molecules that interact with said protein associated with lipid pathways; (b) selecting a protein reporter molecule; (c) effecting fragmentation of said protein reporter molecule such that said fragmentation results in reversible loss of reporter function; (d) fusing or attaching fragments of said protein reporter molecule separately to said interacting protein molecules as defined in step (a); (e) transfecting cells with nucleic acid constructs coding for the products of step (d); (f) reassociating said reporter fragments through interactions of the protein molecules that are fused or attached to said fragments; and (g) measuring directly or Indirectly the activity of said reporter molecule resulting from the reassociation of said reporter fragments.Type: ApplicationFiled: March 6, 2009Publication date: April 1, 2010Applicant: Odyssey Thera, Inc.Inventors: Donna Oksenberg, Drew Sukovich, Tomoe Minami, Jane Lamerdin, John K. Westwick
-
Patent number: 7687539Abstract: The topical use of 5,6,7-trihydroxyheptanoic acid and analogs alone or in combination with histamine antagonists and/or mast cell stabilizers is disclosed for the treatment of ocular allergy.Type: GrantFiled: November 7, 2006Date of Patent: March 30, 2010Assignee: Alcon Research, Ltd.Inventors: Peter G. Klimko, Clay Beauregard
-
Publication number: 20100074951Abstract: Disclosed herein is a lag time delayed-release combination pharmaceutical composition comprising of an angiotensin-II-receptor blocker and an HMG-CoA reductase inhibitor, as well as a preparation method thereof. The composition is designed based on chronotherapy in which active ingredients are administered to have different onset times, such that the release of each active ingredient of the composition in body can be lag time delayed to a specific rate. Also, the composition is very effective for the treatment of hypertension and the prevention of complications in patients having metabolic syndromes which show diabetes, obesity, hyperlipidemia, coronary artery diseases and the like. More specifically, the composition is a drug delivery system designed such that the release of each drug is controlled to a specific rate, and it can show the most ideal effect, when it is absorbed in body.Type: ApplicationFiled: October 30, 2007Publication date: March 25, 2010Applicant: HANALL PHARMACEUTICAL COMPANY, LTD.Inventors: Sung Wuk Kim, Sung Soo Jun, Young Gwan Jo, Ja Seong Koo, Jae Woon Son
-
Publication number: 20100075923Abstract: The present invention is directed to a method of enhancing TGF-? signaling in a subject comprising administering to said subject a clathrin-dependent endocytosis inhibitor in an amount sufficient to enhance TGF-? signaling. In another aspect, the invention is directed to a method of treating a condition associated with decreased TGF-? signaling in a patient in need thereof comprising administering to said patient a clathrin-dependent endocytosis inhibitor in a therapeutically effective amount.Type: ApplicationFiled: September 15, 2009Publication date: March 25, 2010Inventors: Jung San Huang, Shuan Shian Huang
-
Patent number: 7683096Abstract: The present invention relates to an acid amid derivative of the formula (I) or a salt thereof: wherein A is phenyl which may be substituted by X, benzyl which may be substituted by X, naphthyl which may be substituted by X, a heterocyclic group which may be substituted by X, a fused heterocyclic group which may be substituted by X, indanyl (the indanyl may be substituted by halogen, alkyl or alkoxy) or tetrahydronaphthyl (the tetrahydronaphthyl may be substituted by halogen, alkyl or alkoxy), B is alkyl, cycloalkyl, phenyl which may be substituted by Y, a heterocyclic group which may be substituted by Y, or a condensed heterocyclic group which may be substituted by Y, each of R1 and R2 is alkyl, cyano or —CO2R14, or R1 and R2 may together form a 3- to 6-membered saturated carbocyclic ring, R3 is hydrogen, alkyl, alkoxyalkyl, alkylthioalkyl, —COR15, —S(O)mR16 or —S(O)nNR17R18, which is useful as an active ingredient of pesticides.Type: GrantFiled: September 18, 2002Date of Patent: March 23, 2010Assignee: Ishihara Sangyo Kaisha, Ltd.Inventors: Yuji Nakamura, Masayuki Morita, Tetsuo Yoneda, Kenji Izakura
-
Publication number: 20100069392Abstract: The invention relates to the combined use of a PDE4 inhibitor with a HMG-CoA reductase inhibitor for the preventive and curative treatment of an inflammatory pulmonary disease.Type: ApplicationFiled: July 3, 2007Publication date: March 18, 2010Applicant: Nycomed GmbHInventor: Stefan-Lutz Wollin
-
Publication number: 20100063141Abstract: Provided are compounds having an inhibitory effect on sodium-dependent glucose cotransporter SGLT. The invention also provides pharmaceutical compositions, methods of preparing the compounds, synthetic intermediates, and methods of using the compounds, independently or in combination with other therapeutic agents, for treating diseases and conditions that are affected by SGLT inhibition.Type: ApplicationFiled: July 15, 2009Publication date: March 11, 2010Applicant: Theracos, Inc.Inventors: Brian Seed, Binhua LV, Jacques Y. Roberge, Yuanwei Chen, Kun Peng, Jiajia Dong, Baihua Xu, Jiyan Du, Lili Zhang, Xinxing Tang, Ge Xu, Yan Feng, Min Xu
-
Publication number: 20100056552Abstract: There is provided combination products comprising (a) suplatast, or a pharmaceutically-acceptable salt or solvate thereof; and (b) a statin, or a pharmaceutically-acceptable salt or solvate thereof. Such combination products find particular utility in the treatment of atherosclerosis and related conditions.Type: ApplicationFiled: March 31, 2008Publication date: March 4, 2010Inventor: Johan Raud
-
Publication number: 20100055173Abstract: The present invention provides a controlled absorption formulation in which modified release of the active ingredient preferentially occurs in the lower gastrointestinal tract, including the colon. The formulation supports a significantly higher bioavailability of the active ingredient in the body of the subject than that can be achieved from the currently used conventional formulation, such that therapeutically significant plasma levels of statin are maintained for an extended period after administration. The formulation preferably features a core, a subcoat surrounding the core comprising at least one water soluble hydrophilic carrier and an outer coating. The core is optionally and preferably in the form of a tablet.Type: ApplicationFiled: October 9, 2007Publication date: March 4, 2010Inventors: Adel Penhasi, Maxim Gomberg
-
Publication number: 20100048690Abstract: Antitumoral compounds obtained from a porifera, of the family Raspailiidae, genus Lithoplocamia, species lithistoides, and derivatives thereof are provided.Type: ApplicationFiled: June 15, 2007Publication date: February 25, 2010Applicant: PHARMA MAR, S.A.Inventors: Ma Jesus Martin Lopez, Laura Coello Molinero, Jose Fernando Reyes Benitez, Alberto Rodriguez Vicente, Maria Garranzo Garcia-Ibarrola, Carmen Murcia Perez, Andres Francesch Solloso, Francisco Sanchez Sancho, Maria del Carmen Cuevas Marchante, Rogelio Fernandez Rodriguez
-
Patent number: RE41278Abstract: Compositions comprising N-acetyl-aldosamines, N-acetylamino acids, and related N-acetyl compounds are useful to alleviate or improve various cosmetic conditions and dermatological disorders, including changes or damage to skin, nail and hair associated with intrinsic aging and/or extrinsic aging, as well as changes or damage caused by extrinsic factors. N-acetyl-aldosamines, N-acetylamino acids, and related N-acetyl composition may further comprise a cosmetic, pharmaceutical or other topical agent to enhance or create synergetic effects.Type: GrantFiled: November 1, 2006Date of Patent: April 27, 2010Inventors: Ruey J. Yu, Eugene J. Van Scott